Who are Febuxostat IR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): allopurinol sustained-release capsules, AL, Allopurinol Tablet, Bempedoic Acid Tablet, Azathioprine and Allopurinol, Uloric.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/febuxostat-ir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Febuxostat IR — Competitive Intelligence Brief

Febuxostat IR (Febuxostat IR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Xanthine oxidase inhibitor. Area: Rheumatology.

phase 3 Xanthine oxidase inhibitor Xanthine oxidase Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Febuxostat IR (Febuxostat IR) — Takeda. Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Febuxostat IR TARGET	Febuxostat IR	Takeda	phase 3	Xanthine oxidase inhibitor	Xanthine oxidase
allopurinol sustained-release capsules	allopurinol sustained-release capsules	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Xanthine oxidase inhibitor	Xanthine oxidase
AL	AL	Medecins Sans Frontieres, Netherlands	marketed	xanthine oxidase inhibitor	xanthine oxidase
Allopurinol Tablet	Allopurinol Tablet	Haiphong University of Medicine and Pharmacy	marketed	Xanthine oxidase inhibitor	Xanthine oxidase
Bempedoic Acid Tablet	Bempedoic Acid Tablet	Gan & Lee Pharmaceuticals.	phase 3	Uricosuric agent / Xanthine oxidase inhibitor	AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway
Azathioprine and Allopurinol	Azathioprine and Allopurinol	Hvidovre University Hospital	phase 3	Immunosuppressant and xanthine oxidase inhibitor	Purine synthesis pathway (azathioprine); xanthine oxidase (allopurinol)
Uloric	FEBUXOSTAT	Takeda	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Xanthine oxidase inhibitor class)

Haiphong University of Medicine and Pharmacy · 1 drug in this class
Takeda · 1 drug in this class
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Febuxostat IR — Competitive Intelligence Brief. https://druglandscape.com/ci/febuxostat-ir. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab